E
LENZ

Ergoteles’s LENZ Therapeutics LENZ Stock Holding History

Ergoteles’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18,714
Closed -$360K – 2059
2022
Q2 		$360K Buy
+18,714
New +$417K 0.01% 1010
2022
Q1 		– Sell
-10,308
Closed -$897K – 1688
2021
Q4 		$897K Buy
+10,308
New +$854K 0.03% 448

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Ergoteles's LENZ Position: Q3 2022 in Review

Ergoteles sold out of LENZ Therapeutics (LENZ) in Q3 2022, closing a stake of 18,714 shares — an estimated $360K sold.

Ergoteles first reported a position in LENZ in Q4 2021 and held it in 2 quarters. The position peaked at $897K in Q4 2021. 63 funds tracked by Wall St. Rank hold LENZ as of Q3 2022.

  • Ergoteles reported no remaining LENZ Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 18,714 LENZ Therapeutics shares in Q3 2022, an estimated $360K.
  • Ergoteles first reported a position in LENZ Therapeutics in Q4 2021 and held it in 2 quarters.
  • Ergoteles's LENZ Therapeutics position peaked at $897K in Q4 2021.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.